Heron Therapeutics appoints Thomas Cusack to board of directors

Heron Therapeutics Inc. (NASDAQ: HRTX) announced the appointment of Thomas Cusack to its board of directors, effective October 27, 2025. The appointment was made pursuant to a cooperation agreement between the biotechnology company and Rubric Capital Management LP dated August 8, 2025.

Cusack brings more than 20 years of experience in investment management and corporate finance. He served as managing director of Starboard Value LP from 2011 to 2025, working at the New York-based investment fund that manages approximately $9 billion in assets. At Starboard Value, Cusack evaluated investment opportunities, developed operating strategies and worked with boards and management teams on performance improvement and corporate governance matters.

Prior to Starboard Value, Cusack worked as an investment banker at Barclays Capital and Lehman Brothers from 2006 to 2011, focusing on mergers and acquisitions in the technology, media and telecom sectors. He holds a bachelor's degree in finance and accounting from New York University's Leonard N. Stern School of Business.

"We are pleased to welcome Tom to Heron's Board of Directors," said Craig Collard, chief executive officer of Heron. "Tom will undoubtedly bring a wealth of perspective to benefit our efforts to build momentum at Heron."

Heron Therapeutics describes itself as a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations for acute care and oncology patients. The information is based on a company press release.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• LivePerson extends special meeting deadline for SoundHound AI merger vote
• Singularity Future Technology closes $5M registered direct offering